Nominations now open — Submit before 15 December 2026 · Free to enterSubmit Now

Pharmacogenomics Becomes a Pharmacy Workflow Test

★
Editorial Team
DATENov 20, 2026
Pharmacogenomics Becomes a Pharmacy Workflow Test

Pharmacogenomics is frequently introduced as a scientific breakthrough: a patient's genetic profile is analyzed, a specific variant is identified, and a medication is selected or dosed with a precision far exceeding traditional trial-and-error methods. While this description of the science is accurate, it is incomplete. For the healthcare institution, the most complex challenge begins only after the laboratory report arrives. A genotype is merely a document; a prescribing decision is an action. The distance between these two points is filled with necessary processes: interpretation, documentation, alert design, professional accountability, and rigorous follow-up.

This operational gap is widening as pharmacogenomic testing becomes more widely available. Panels that were once confined to research settings are now routinely ordered by specialist clinics and, increasingly, by general hospital teams. Results arrive in varying formats, with differing levels of inherent interpretation and varying assumptions about who will act upon them. Consequently, the limiting factor is less often the underlying science and more frequently the institution's ability to translate a raw genetic result into a safe, timely, and auditable prescribing decision.

The 2026 Global Healthcare Awards’ focus on practical innovation, safety, and accountable care delivery reflects this critical shift. Pharmacogenomics is not solely a precision medicine narrative; it is fundamentally a test of pharmacy operations and clinical governance.

A Result Is Not Yet a Prescribing Decision

The first governance hurdle is ownership. When a pharmacogenomic result is filed within a patient record, who is explicitly responsible for reviewing it? In many organizations, the honest answer is that no single party is accountable. The report lands in the record, the ordering clinician may have moved to another patient, and the subsequent prescriber encounters a complex document they did not request and may not feel equipped to interpret.

Accountable workflows close this gap by clearly naming the reviewing role. This may be a clinical pharmacist with pharmacogenetics training, a dedicated specialist service, or a designated group within pharmacy and pathology. Crucially, this responsibility must be documented, resourced, and visible within the patient record, rather than left to assumption.

Interpretation is the second step. A genotype does not prescribe; it provides guidance. Consensus resources, such as those developed by pharmacogenetics implementation consortia, translate variants into suggested actions for specific drugs and genes—for example, those affecting thiopurine metabolism, fluoropyrimidine tolerance, or the handling of certain antidepressants and opioid analgesics. Hospitals must establish a local policy on which of these external recommendations they endorse, how they are worded, and who has the authority to amend them as clinical guidance evolves.

Ambiguity also requires a defined pathway. Variants of uncertain significance, results originating outside the requested gene, and findings with implications for relatives all demand a documented protocol. This applies equally to the awkward scenario of a result arriving years after the prescription it pertains to. Without a clear pathway, ambiguous findings tend to either be over-interpreted by cautious clinicians or quietly ignored.

Alerting That Earn Attention

Clinical decision support is where pharmacogenomics most visibly succeeds or fails. The natural temptation is to trigger an alert whenever a result is relevant to an ordered medicine. The predictable consequence of this approach is that clinicians learn to dismiss pharmacogenomic warnings, causing useful alerts to lose their force amidst the noise.

Effective design begins with specificity. An alert must differentiate between guidance that is strongly actionable and information that is merely contextual. It should appear precisely at the point where a prescribing decision is made—during order entry, verification, or reconciliation—rather than buried in a results inbox that is rarely monitored. Furthermore, the alert must reflect the patient's current medication list, because a patient's apparent metabolizer status can be altered by interacting drugs, meaning a warning based solely on the genotype may be misleading.

Durability is equally important. Genetic results must remain visible and interpretable across all care settings, including transitions between inpatient and ambulatory systems. They must also survive system upgrades to order sets and alert logic. Someone must own the rules after go-live, with a clear mechanism for clinicians to report an alert that is incorrect, mistimed, or missing.

Pharmacy as the Integrating Function

Pharmacists are already positioned at the critical junctures where pharmacogenomic guidance must be applied: medication reconciliation upon admission, verification of orders, interaction review, counseling, and discharge planning. This makes pharmacy the natural integrating function, provided the role is clearly defined rather than absorbed informally into an already stretched workload.

A workable model specifies who reviews incoming results, how the interpretation is documented in structured fields rather than free text or scanned attachments, and how this information is communicated to the prescriber and, where appropriate, to the patient. It must also anticipate timing. A test ordered during an acute admission may not return before discharge, meaning the workflow must carry the necessary guidance into the discharge summary and the handover to primary care, or the result risks being rediscovered only by accident.

Training and reference material are not a one-off launch exercise; they must be integrated into routine practice. Pharmacists tasked with acting on genetic information require a consistent local standard for what the result means and what the institution expects them to do with it.

Consent, Reuse and Equity

Genetic data behaves differently from most traditional clinical information. It is inherently identifiable, stable, carries implications for relatives, and can be reanalyzed as scientific knowledge advances. Consent obtained for a single drug-gene test may not adequately cover long-term storage, secondary use, or later reinterpretation. Hospitals must be able to state plainly what data is retained, for how long, who may access it, and how a patient's questions regarding data reuse are answered.

Equity represents a quieter, yet more significant, risk. If access to testing depends on specialist referral, clinician initiative, or the patient's ability to pay, the benefits of pharmacogenomics will inevitably concentrate among the patients who already receive the most attention. Furthermore, reference datasets and allele frequency assumptions do not travel perfectly across all ancestries, which impacts the confidence with which a result can be interpreted for certain patient groups. Institutions that actively monitor who is tested and who returns for follow-up are best positioned to identify gaps before they solidify into an inequitable standard of care.

Laboratory Contracts and the Long Tail of Monitoring

A significant portion of the operational risk resides outside the hospital, within the arrangements made with external laboratories. Contracts and service specifications must clearly set expectations for ordering menus, turnaround times, the format of results, whether structured data or documents are returned, how interpretations are updated when clinical guidance changes, and what clinical support the laboratory will provide when a result is unclear.

None of this can be assumed to be static. A functional workflow at the time of go-live is not evidence of a reliable one a year later. Effective monitoring requires asking: Are results being acted upon? Are alerts being overridden, and why? Did prescribing actually change in the intended direction? Did safety events occur? Does the process function equally well during off-hours, on weekends, and across different hospital sites?

Pharmacogenomics will continue to be described as a frontier of precision medicine, and in research terms, it is. Inside the hospital, the more decisive question is far more mundane: when a result arrives, does anyone know whose job it is to act on it, and can the institution demonstrate that the answer held? The 2026 Global Healthcare Awards recognize practical innovation and accountable delivery precisely because this operational question—not the elegance of the assay—determines whether patients truly benefit.